

EVALUATION OF EFFICACY AND SAFETY OF REGORAFENIB IN METASTATIC COLON CANCER


M. Piñero¹, C. Sobrino², V. Morales¹, L. Laguna¹, M.A. Padrón¹, S. Marrero¹, L. Oliva¹, M. León¹, M. Amat¹
1. Hospital Universitario de Gran Canaria Dr. Negrín / 2. Hospital Universitario La Paz

BACKGROUND

Treatment with regorafenib is an alternative third-line therapy for patients with metastatic colon cancer. This new treatment option was marketed in 2013, so it should be checked whether the efficacy and safety in routine clinical practice are equivalent to those reported in pivotal trials.

PURPOSE: To assess the efficacy and safety of regorafenib in the treatment of metastatic colon cancer in routine clinical practice in a tertiary hospital.



MATERIAL AND METHODS



Data were recorded from Computerized Clinical History and Pharmaceutical Dispensing Software.

RESULTS

Ten patients, 6 (60%) men and 4 (40%) women, were studied. Mean age was 60.8 years. All patients were diagnosed with metastatic colon cancer. Mean OS was 5.25 months and mean PFS was 2.55 months. Notified adverse reactions were: hand-foot syndrome (4), diarrhea (2), asthenia (6), decreased intake (4), mucositis (2) and emetic syndrome (2). All patients had at least one adverse event and 80% required a full dose reduction for toxicity and / or bad tolerance.



CONCLUSIONS

Results of **efficacy** of regorafenib in metastatic colon cancer therapy in routine clinical practice were inferior to those reported in pivotal trials (6.4 months OS in CORRECT or 8.8 months in CONCUR vs 5.25 months).

Safety profile was similar to that described in data sheet, however frequency of patients requiring dose reduction (80%) was higher than expected.

In conclusion, comparing older alternatives efficacy (Regorafenib PFS 1.9 months, Panitumumab PFS 1.9 months, Cetuximab PFS 3.7 months, Best supportive care PFS 1.2 months), the **use of an alternative** in third-line treatment for metastatic colon cancer should be based on its safety profile and patient tolerance.

No conflict of interest.